Mezigdomide

A pharmaceutical drug used in cancer treatment

Mezigdomide
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Mezigdomide is a pharmaceutical drug that is primarily used in the treatment of certain types of cancer. It belongs to a class of drugs known as immunomodulatory drugs (IMiDs), which are known for their ability to modulate the immune system and inhibit tumor growth.

Mechanism of Action

Mezigdomide functions by modulating the activity of the immune system. It binds to the protein cereblon, which is part of the E3 ubiquitin ligase complex. This binding leads to the degradation of specific transcription factors that are essential for the survival and proliferation of cancer cells. By targeting these proteins, Mezigdomide can induce apoptosis, or programmed cell death, in cancer cells, thereby reducing tumor growth.

Clinical Uses

Mezigdomide is used in the treatment of various hematological malignancies, including multiple myeloma and certain types of lymphoma. It is often used in combination with other chemotherapeutic agents to enhance its efficacy. The drug is administered orally, making it a convenient option for patients.

Side Effects

Like many cancer treatments, Mezigdomide can cause a range of side effects. Common side effects include fatigue, nausea, and diarrhea. More serious side effects can include neutropenia, which is a decrease in white blood cells, increasing the risk of infection. Patients are monitored closely for these side effects during treatment.

Development and Approval

Mezigdomide was developed as part of ongoing research into IMiDs, following the success of earlier drugs in this class such as thalidomide and lenalidomide. It has undergone extensive clinical trials to establish its safety and efficacy in treating cancer. The drug received approval from regulatory agencies after demonstrating significant benefits in clinical outcomes for patients with specific types of cancer.

Research and Future Directions

Ongoing research is exploring the potential of Mezigdomide in treating other types of cancer and in combination with new therapeutic agents. Studies are also investigating its role in modulating the immune system in other diseases beyond cancer.

Related Pages

• Immunomodulatory drugs
• Multiple myeloma
• Cancer treatment
• Thalidomide
• Lenalidomide